Plasma miR-200c-3p, miR-100-5p, and miR-1826 serve as potential diagnostic biomarkers for knee osteoarthritis

Randomized controlled trials

Zhen Lai, MDa, Yanguang Cao, MD*b,*

Abstract
Objective: To study the potential diagnostic value of plasma miR-200c-3p, miR-100-5p, and miR-1826 levels in knee osteoarthritis (KOA).

Methods: Real-time quantitative PCR (RT-PCR) was used to measure the expression levels of serum miR-200c-3p, miR-100-5p, and miR-1826 in 150 KOA patients and 150 control controls. In addition, the levels of DNMT3A, ZEB1, and CTNNB1 mRNAs in the synovial fluid were also measured by RT-PCR.

Results: The expression levels of miR-100-5p, miR-200c-3p, and miR-1826 in the synovial fluid of 150 KOA patients were significantly lower than those in 54 controls (P < .001). In the synovial fluid, the miR-100-5p and DNMT3A mRNA levels, miR-100-5p and ZEB1 mRNA levels, and miR-1826 and CTNNB1 mRNA levels were all negatively correlated (r = −0.83, −0.81, −0.83, −0.58, respectively). The AUCs of the diagnosis for KOA using the plasma levels of miR-200c-3p, miR-100-5p, and miR-1826 were 0.755, 0.845, and 0.749, respectively.

Conclusion: The plasma levels of miR-200c-3p, miR-100-5p, and miR-1826 are of potentially high value in the diagnosis of KOA.

Abbreviations: AUC = the area under the curve, BMI = body mass index, CTNNB1 = catenin beta 1, DNMT3A = DNA methyltransferase 3 alpha, EDTA = ethylenediaminetetraacetic acid, KOA = knee osteoarthritis, MMP13 = matrix metalloproteinase 13, OA = osteoarthritis, ROC = receiver operating curve, RT-PCR = Real-time quantitative PCR, SD = standard deviation, ZEB1 = zinc finger E-box binding homeobox 1.

Keywords: biomarker, knee osteoarthritis, miR-100-5p, miR-1826, miR-200c-3p

1. Introduction

Osteoarthritis (OA) is a common chronic and progressive joint disease that occurs in middle-aged and elderly people. The clinical manifestations are different degrees of joint swelling and pain, limited mobility, and other symptoms. The pathological features are a progressive destruction of the articular cartilage and subchondral bone, and synovial inflammation of the joints.[1,2] In recent years, the incidence of knee osteoarthritis (KOA) has been on the rise, and it has become the primary factor that causes pain and disability in the elderly.[3] Owing to the poor ability of articular cartilage to repair itself, and the limited efficacy of the currently used conservative treatment, most patients need artificial knee replacements as the disease progresses.[4] According to several studies, biochemical changes in the damaged articular cartilage precede morphological changes, so an ability to detect relevant enzymes and cytokines, as well as other biological markers, in body fluids (e.g., synovial fluid, serum, or urine) from patients could provide a new means for the early diagnosis of KOA.[5–7]

MicroRNAs (miRNAs) are known to be involved in the development of numerous diseases such as cancer,[8] liver fibrosis and cirrhosis,[9] and OA.[10] To maintain cartilage, chondrocytes upregulate anabolic and catabolic processes by responding to growth factors and cytokines. Studies have shown that miRNAs are involved in regulating the expression of genes in the signaling pathway that controls cartilage transformation.[11,12] Studies have shown that the interaction between miR-200c-3p and ZEB1 may contribute to chondrocyte hypertrophy, so that chondrocytes change from a quiescent state to a proliferative state, and then differentiate.[13] The important role of miR-100-5p in the pathogenesis of various cancers has been confirmed by many
studies.\textsuperscript{14,15} miR-1826 is involved in the occurrence and development of malignant tumors. Studies have found that the upregulation of miR-1826 may be a marker of the prognosis of CRC, and could be a potential therapeutic target for the treatment of CRC.\textsuperscript{16}

The action of miRNAs is also crucial in the occurrence and development of KOA. At present, a variety of miRNAs with potential diagnostic KOA values have been predicted by computational means, and include miR-200c-3p, miR-100-5p, and miR-1826.\textsuperscript{17} This study aimed to investigate the potential value of plasma miR-200c-3p, miR-100-5p, and miR-1826 levels in the diagnosis of KOA.

2. Materials and methods

2.1. General information

From February 2015 to March 2018, this study enrolled 150 patients with KOA (KOA group), aged 35 to 87 years, with an average age of 58.33 ± 11.13 years. The American College of Rheumatology diagnostic KOA criteria were used for patient diagnosis.\textsuperscript{18} The severity of KOA was classified according to the Kellgren and Lawrence scoring systems, and included 75 patients with grade 2, 54 patients with grade 3, and 21 patients with grade 4. We recruited 150 non-KOA patients as a control group. These patients included 54 cases of traumatic amputation or meniscus injury surgery, and 96 healthy subjects. All the control patients had Kellgren and Lawrence scores of 0. The study protocol was approved by our ethics committee, and all participants in the study signed an informed consent form.

2.2. RNA extraction

Approximately 10mL of venous blood was collected from all patients in an ethylenediaminetetraacetic acid (EDTA) collection tube, allowed to stand for 2 hours, and then centrifuged at 13,000r/min for 25 minutes within 1 hour after sampling, and the supernatant was stored in an Eppendorf tube at 80°C. Total RNA was purified using the AllPrep DNA/RNA Micro kit (Qiagen, Valencia, CA).

2.3. cDNA synthesis

cDNA synthesis was performed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, CA). From the kit protocol, \(10 \times \) RT buffer, dNTP mix w/dTTP (100 M total), RNase inhibitor (20 U/μL), MultiScribeTM RT enzyme (50 U/μL), water, and primers were then used to extract total RNA as a template to synthesize cDNA.

2.4. Real-time quantitative PCR (RT-PCR)

The synthesized cDNA was used as a template, using primers with the sequences shown in Table 1 for the RT-PCR reaction, and an ABI 7900 HT Fast Real-Time PCR system (Applied Biosystems). The RT-qPCR conditions were as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 60 seconds. The expression levels of miRNAs relative to U6 were calculated using the 2-ΔΔCt method.

| miR-200c-3p | Forward: 5'-GGG GTA GGG GAA GGT GGT TTA-3' |
| miR-100-5p | Reverse: 5'-CAC CCC AAC AAT CCC TAA AAA CAC T-3' |
| miR-1826   | Forward: 5'-CGG ATT TAA AAA CAG GGA GAA AGA-3' |
| MMP13      | Forward: 5'-GGG TTA AGG CAC ACC TCA GAT C-3' |
| U6         | Forward: 5'-GGA GCG TTC AGG AAG TTA C-3' |
| DNM3A      | Reverse: 5'-ACT GAA AGG GTG TCA CTG TCC GAC-3' |
| ZEB1       | Reverse: 5'-ATT AGA AGG GTG TCA CTG TCC GAC-3' |
| CTNNB1     | Reverse: 5'-ACT GAA AGG GTA CCG GTT GTA GGA AGA-3' |

2.5. Western blotting to detect protein expression levels

Articular cartilage was obtained from 3 KOA patients and 3 control subjects. These samples were used for western blotting to detect the protein levels of DNM3A (anti-human DNM3A antibody, #681615, R&D systems, Minneapolis, MN, USA), ZEB1 (anti-human ZEB1 antibody, #639914, R&D Systems), MMP13 (anti-human MMP13 antibody, #87512, R&D Systems), and CTNNB1 (anti-human CTNNB1 antibody, #196621, R&D Systems). The protein concentration in the cartilage samples was quantified using a BCA Kit (Sigma-Aldrich, St Louis, MO). Protein extracts were transferred to PVDF membranes, blocked with 5% skimmed milk in TBST (Tris-buffered saline and Polysorbate 20 (Tween 20) containing 50mM Tris, 150mM NaCl, 0.1% Tween 20), and then incubated with the appropriate primary antibody overnight at 4°C. The membranes were then incubated for 1 hour at room temperature with the secondary antibody, after which the proteins were detected using an enhanced chemiluminescence (ECL) (GE Healthcare, Chalfont St Giles, Bucks, UK) reagent.

2.6. Statistical analysis

The categorical variables are expressed as a percentage [n (%)] and a statistical analysis was performed using a Chi-square test (\(\chi^2\)). Continuous variables are expressed as mean ± SD and the statistical analysis was performed using an independent sample t.test. The receiver Operating Curve (ROC) and the area under the curve (AUC) were used to evaluate the value of miRNAs in the diagnosis of KOA. P < .05 indicated that the difference was statistically significant.

3. Results

3.1. Demographic characteristics

Of the 150 patients with KOA, 84 were male and 66 were female, with ages in the range of 35 to 87 years, and a BMI range of 18.9 to 29.8 kg/m². Of the 150 healthy controls, 88 were male and 62
were female, with ages in the range of 35 to 85 years and a BMI range of 18.9 to 31.5 kg/m². Using the Kellgren–Lawrence scale, 75 cases were found to be grade 2, 54 cases were grade 3, and 21 cases were grade 4. There were no significant differences in age, gender, BMI, KOA family history, smoking history, drinking history, and other general data, between the KOA group and the healthy control group ($P > .05$) (Table 2).

### 3.2. Expression of miRNAs

The expression levels of miR-100-5p, miR-200c-3p, and miR-1826 in the synovial fluid from the 52 KOA patients, and the 150 healthy controls were analyzed. The results showed that the expression levels of miR-100-5p, miR-200c-3p, and miR-1826 were significantly lower in the synovial fluid from the KOA patients compared with those in the healthy control group, and this difference was statistically significant ($P < .001$) (Figs. 1 and 2).

### 3.3. Expression levels for the miRNA target proteins

The expression levels of DNMT3A, ZEB1, MMP13, and CTNNB1 in articular cartilage were assessed by western blotting. The data showed that in the articular cartilage from KOA patients the levels of DNMT3A, ZEB1, MMP13, and CTNNB1 were significantly higher than those in the cartilage from control healthy patients, as shown in Figure 3.

### 3.4. Correlation between miRNAs expression levels in synovial fluid and the corresponding target mRNA levels

RT-PCR was used to assess both the expression levels of miRNAs in synovial fluid and the levels of their target mRNAs. The results showed that the miR-100-5p levels were negatively correlated with $DNMT3A$ mRNA levels ($r = -0.83$, Fig. 4A), and negatively correlated with $ZEB1$ mRNA levels ($r = -0.81$, Fig. 4B). In addition, the miR-200c-3p levels were negatively correlated with the $MMP13$ mRNA levels ($r = -0.83$, Fig. 4C), and the miR-1826 levels were negatively correlated with $CTNNB1$ mRNA levels ($r = -0.58$, Fig. 4D).

### Table 2

| General information. | KOA group (n = 150) | Control group (n = 150) | $P$ value |
|----------------------|--------------------|------------------------|----------|
| Age (years, mean± SD) | 58.33±11.13        | 58.61±8.19             | .80      |
| Gender [n (%)]        |                    |                        |          |
| Male                 | 84 (56.00%)        | 88 (58.67%)            | .64      |
| Female               | 66 (44.00%)        | 62 (41.33%)            |          |
| Body mass index (kg/m², mean± SD) | 24.91±2.42 | 25.07±2.65 | .59 |
| Family history [n (%)] |                  |                        |          |
| Yes                  | 15 (10.00%)        | 10 (6.67%)             | .30      |
| No                   | 135 (90.00%)       | 140 (93.33%)           |          |
| Smoking [n (%)]       |                    |                        |          |
| Yes                  | 61 (40.67%)        | 58 (38.67%)            | .72      |
| No                   | 89 (59.33%)        | 92 (61.33%)            |          |
| Alcohol consumption [n (%)] |                |                        |          |
| Yes                  | 65 (43.33%)        | 61 (40.67%)            | .64      |
| No                   | 85 (56.67%)        | 89 (59.33%)            |          |
| Kellgren-Lawrence grading |             |                        |          |
| 2                    | 75 (50.00%)        |                        |          |
| 3                    | 54 (36.00%)        |                        |          |
| 4                    | 21 (14.00%)        |                        |          |

BMI = body mass index, KOA = knee osteoarthritis.
3.5. Utility of plasma miRNAs to diagnose KOA using an ROC curve

The AUC for miR-200c-3p levels in the plasma was 0.755, the sensitivity was 82.00%, and the specificity was 82.00% (Fig. 5A). The AUC for miR-100-5p levels in the plasma was 0.845, the sensitivity was 82.00%, and the specificity was 86.00% (Fig. 5B). The AUC for plasma miR-1826 levels in the plasma was 0.749 with a sensitivity of 82.00% and a specificity of 86.00% (Fig. 5C).

4. Discussion

KOA is a degenerative joint disease that can cause damage to articular cartilage tissue.19 As the population ages, more and more elderly people in China are threatened by KOA.20

Figure 3. Detections of DNMT3A, ZEB1, MMP13, and CTNNB1 protein expression in articular cartilage tissue. Target gene/internal reference control gray value comparison. A: KOA (1.36), Control (0.64); B: KOA (1.28), Control (0.63); C: KOA (1.34), Control (0.59); D: KOA (1.96), Control (0.49).

Figure 4. Correlation of miRNAs expression levels with their target mRNA levels. A is the correlation between miR-200c-3p expression level and DNMT3A mRNA level in synovial fluid; B is the correlation between miR-200c-3p expression level and ZEB1 mRNA level in synovial fluid; C is the correlation between miR-100-5p expression level and MMP13 mRNA level in synovial fluid; D is the correlation between miR-1826 expression level and CTNNB1 mRNA level in synovial fluid.
Some researchers have shown that miR-200c-3p has six related target proteins, namely FGFR3, FLT1, ID1, IGF1R, MMP13, and PLK1. The target most relevant to KOA is matrix metalloproteinase 13 (MMP-13), which is a central node in the cartilage degradation network. MMP-13 levels and activities in OA chondrocytes are associated with upstream regulatory factors, DNA methylation, and various non-coding RNAs (ncRNAs). The results of this study showed that miR-100-5p levels in the plasma and synovial fluid of patients with KOA were lower than those in healthy controls, whereas MMP13 expression in the articular cartilage was higher than that in the control group. Analysis of the miR-100-5p levels and MMP13 mRNA levels in the synovial fluid of the joint showed that the 2 were negatively correlated, indicating that miR-100-5p is involved in the negative feedback regulation of MMP13 expression.

At present, the treatment of patients with KOA is a mainly conservative treatment plan that reduces pain and inflammation, but is not curative, and drug treatment often causes side effects. Therefore, it is important to explore the pathogenesis of KOA and study diagnostic and preventive measures for the treatment of KOA.

miRNAs play an important role in the regulation of many signaling pathways, especially those involved in gene regulation. Previous studies have compared the expression of 365 miRNAs in the joint tissues of 10 normal controls and 33 OA patients, and explored the role of miRNAs in the pathogenesis of OA. In the knee joint, cartilage is mainly comprised of the extracellular matrix (ECM) and chondrocytes. Chondrocytes maintain cartilage by up-regulating anabolic and catabolic processes in response to growth factors and cytokines. miRNAs play an important role in the regulation of the signaling pathways used by these growth factors and cytokines. For example, miR-140 plays an important role in the development of cartilage during aging and OA. Some researchers have confirmed the importance of integrating information about miRNA targets and OA-related genes. Using a computer simulation model, 12 miRNAs have been predicted to have a potential diagnostic value for KOA. Among these, miR-200c-3p, miR-100-5p, and miR-1826 were not found to be related to the occurrence and development of KOA.

It has been shown that miR-200c-3p has a variety of downstream regulatory targets that are associated with a variety of processes, including apoptosis (BCL2, XIAP), the up-regulation of MMPs (VEGFA), chondrocyte hypertrophy (FLT1, JAG1, VEGFA), ECM maintenance (ERFII1, FN1), inflammation (IKBKB, NTRK2, VEGFA), angiogenesis (TIMP2, VEGFA), and cytoskeleton maintenance (TUBB3). In addition, 5 target proteins have been found to be involved in the maintenance of cartilage, chondrocyte hypertrophy, and OA pathogenesis, namely DNMT3A, DNMT3B, NOTCH1, SP1, and ZEB1. In this study, 2 miR-200c-3p target proteins were selected for analysis, namely DNMT3A and ZEB1. The analysis revealed that the expression levels of miR-200c-3p and DNMT3A and ZEB1 were negatively regulated. Low levels of miR-200c-3p were detected in the blood and synovial fluid from KOA patients, whereas the expression levels of DNMT3A and ZEB1 in synovial fluid and chondrocytes were higher than those in the control group. Consistent with the results of Bellon et al., the interaction between miR-200c-3p and DNMT3A and ZEB1 may contribute to chondrocyte hypertrophy, so that chondrocytes change from a quiescent state to a proliferative state and then differentiate.

miR-100-5p has six related target proteins, namely FGFR3, FLT1, ID1, IGF1R, MMP13, and PLK1. The target most relevant to KOA is matrix metalloproteinase 13 (MMP-13), which is a central node in the cartilage degradation network. MMP-13 levels and activities in OA chondrocytes are associated with upstream regulatory factors, DNA methylation, and various non-coding RNAs (ncRNAs). The results of this study showed that miR-100-5p levels in the plasma and synovial fluid of patients with KOA were lower than those in healthy controls, whereas MMP13 expression in the articular cartilage was higher than that in the control group. Analysis of the miR-100-5p levels and MMP13 mRNA levels in the synovial fluid of the joint showed that the 2 were negatively correlated, indicating that miR-100-5p is involved in the negative feedback regulation of MMP13 expression.

From the miRTarBase it can be predicted that miR-1826 targets only 3 genes that are associated with the development and progression of OA, namely CTNNB1, MAP2K1, and VEGFC. CTNNB1 encodes the protein β-catenin, which is a key component of the Wnt signaling pathway, MAP2K1 encodes a kinase involved in MAPK/ERK signaling, and VEGFC encodes a VEGF receptor. In this study, the CTNNB1 protein was selected for analysis to investigate the correlation between the expression of miR-1826 and the expression of CTNNB1 in the plasma and synovial fluid. The results showed that the levels of miR-1826 in synovial fluid are negatively correlated with CTNNB1 mRNA levels. The level of miR-1826 in the plasma and synovial fluid of KOA patients was significantly lower than that in healthy controls whereas the CTNNB1 protein levels were higher than those in the healthy controls. Currently, no other studies have shown that miR-1826 levels and CTNNB1 expression are associated with the occurrence of KOA. Hirata et al. found that miR-1826 plays an important role as a tumor suppressor by down-regulating CTNNB1/MEK1/VEGFC in breast cancer. They showed that CTNNB1 MEK1 and VEGFC are direct targets of miR-1826, and that there is a negative correlation between miR-1826 levels and CTNNB1, MEK1, or VEGFC protein expression, which is consistent with the results of this study.

Through an ROC curve analysis, we also found that plasma levels of miR-200c-3p, miR-100-5p, and miR-1826 have high diagnostic value for the diagnosis of KOA since the AUCs were higher than 0.5. These findings provide an alternative approach...
to the diagnosis of clinical KOA. However, this study also has some limitations. First, our sample size was small, and the results have not yet been confirmed with a larger sample size. In addition, we have not studied the regulatory mechanisms of these miRNAs and their related target proteins in an in vitro model. Moreover, because the acquisition of tissue samples is difficult, only a small number of tissue samples were obtained. Finally, limited by the sample size, we did not strictly distinguish between patients with different degrees of KOA severity.

In summary, the expression levels of miR-200c-3p, miR-100-5p, and miR-1826 in the plasma of KOA patients are abnormal and may be of high value for the diagnosis of KOA.

Author contributions

Conceptualization: Yanguang Cao.

Data curation: Zhen Lai.

Formal analysis: Zhen Lai.

Funding acquisition: Zhen Lai.

Methodology: Zhen Lai.

Supervision: Yanguang Cao.

Writing – original draft: Zhen Lai.

Writing – review & editing: Yanguang Cao.

References

[1] Pereira D, Ramos E, Branco J. Osteoarthritis. Acta Med Port 2015;28:99–106.
[2] Bleas A, Das Neves Borges P, Curtinha M, et al. Studying osteoarthritis pathogenesis in mice. Curr Protoc Mouse Biol 2018;8:e50.
[3] Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1323–30.
[4] Pan F, Ding C, Winzenberg T, et al. The offspring of people with a total knee replacement for severe primary knee osteoarthritis have a higher risk of worsening knee pain over 8 years. Ann Rheum Dis 2016;75:368–73.
[5] Ahmed U, Anwar A, Savage RS, et al. Protein oxidation, nitration and glycation biomarkers for early-stage diagnosis of osteoarthritis of the knee and typing and progression of arthritic disease. Arthritis Res Ther 2016;18:250.
[6] de Bakker E, Stroobants V, VanDael F, et al. Canine synovial fibrosis and microRNAs and their related target proteins in an in vitro model. Osteoarthritis Cartilage 2016;24:573–80.
[7] Li W, Du C, Wang H, et al. Increased serum ADAMTS-4 in knee osteoarthritis: a potential indicator for the diagnosis of osteoarthritis in early stages. Genet Mol Res 2014;13:9642–9.
[8] Singh R, Ramasubramanian B, Kanj S, et al. Circulating microRNAs in cancer: hope or hype? Cancer Lett 2016;381:113–21.
[9] Fernandez-Ramos D, Fernandez-Tussy P, Lopitz-Otxoa F, et al. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. Cell Death Dis 2018;9:958.
[10] Beyer C, Zampetaki A, Lin NY, et al. Signature of circulating microRNAs in osteoarthritis. Ann Rheum Dis 2015;74:e18.
[11] Liang ZJ, Zhuang H, Wang GX, et al. MiRNA-140 is a negative feedback regulator of MMP-13 in IL-1beta-stimulated human articular chondrocyte C28/I2 cells. Inflamm Res 2012;61:503–9.
[12] Crowe N, Stedges TE, Le LT, et al. Detecting new microRNAs in human osteoarthritic chondrocytes identifies miR-3085 as a human, chondrocyte-selective, microRNA. Osteoarthritis Cartilage 2016;24:534–43.
[13] Magenta A, Cencioli C, Fasanaro P, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2013;18:1628–39.
[14] Nabavi N, Saidy NR, Venalainen E, et al. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Sci Rep 2017;7:4079.
[15] Chen F, Lin C, Quan J, et al. Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma. Mol Med Rep 2017;16:5023–30.
[16] Hu Y, Yi B, He S, et al. Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer. Anticancer Agents Med Chem 2016;16:1109–16.
[17] Proctor CJ, Smith GR. Computer simulation models as a tool to investigate the role of microRNAs in osteoarthritis. PLoS One 2017;12:e0187568.
[18] Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49.
[19] Chu CR, Millis MB, Olson SA. Osteoarthritis: from palliation to prevention; AOA critical issues. J Bone Joint Surg Am 2014;96:e130.
[20] Tang X, Wang S, Zhan S, et al. The prevalence of symptomatic knee osteoarthritis in China: results from the China health and retirement longitudinal study. Arthritis Rheumatol 2016;68:648–53.
[21] Bert JM, Endres NK, Tucker CJ, et al. The conservative treatment of osteoarthritis of the knee. Orthopedics 2018;41:256–60.
[22] Smith PA. Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis: an FDA-sanctioned, randomized, double-blind, placebo-controlled clinical trial. Am J Sports Med 2016;44:884–91.
[23] Duyymus TM, Muthu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Sports Traumatol Arthrosc 2017;25:485–92.
[24] Martinez NJ, Wallow AJ. The interplay between transcription factors and microRNAs in genome-scale regulatory networks. Bioessays 2009;31:435–45.
[25] Nugent M. MicroRNAs: exploring new horizons in osteoarthritis. Osteoarthritis Cartilage 2016;24:573–80.
[26] Songad GR, Haqqi TM. The role of MicroRNAs and their targets in osteoarthritis. Curr Rheumatol Rep 2016;18:56.
[27] Papayoanou G, Mirzamohammadi F, Lisse TS, et al. MicroRNA-140 provides robustness to the regulation of hypertrophic chondrocyte differentiation by the PTHrP-HDAC4 pathway. J Bone Miner Res 2015;30:1044–52.
[28] Zhang R, Ma J, Yao J. Molecular mechanisms of the cartilage-specific microRNA-140 in osteoarthritis. Inflamm Res 2013;62:871–7.
[29] Bellon E, Luyten FP, Tylzanowski P. delta-EF1 is a negative regulator of Ihh in the developing growth plate. J Cell Biol 2009;187:685–99.
[30] Li H, Wang D, Yuan Y, et al. New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res Ther 2017;19:248.
[31] Tribulo P, Moss JI, Ozawa M, et al. WNT regulation of embryonic development likely involves pathways independent of nuclear CTNNB1. Reproduction 2017;153:405–19.
[32] Arcila ME, Drilon A, Sylvester BE, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res 2015;21:1935–43.
[33] Dubois M, Giuliano S, Ambrosetti D, et al. Sunitinib stimulates expression of VEGF-C by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res 2017;77:1212–26.
[34] Hirata H, Hinoda Y, Ueno K, et al. MicroRNA-1826 targets VEGF-C, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 2012;33:41–8.